Olema Pharmaceuticals (OLMA) Free Cash Flow (2020 - 2026)

Olema Pharmaceuticals (OLMA) has reported Free Cash Flow for 7 consecutive years, with -$46.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Free Cash Flow fell 4.57% year-over-year to -$46.0 million; the TTM figure through Mar 2026 stood at -$148.7 million (down 19.13% YoY), while the FY2025 annual figure was -$146.7 million, down 40.38% from the prior year.
• Free Cash Flow eased to -$46.0 million in Q1 2026 per OLMA's latest filing, from -$38.3 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$17.9 million in Q1 2022 and bottomed at -$46.0 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$27.3 million across 5 years, with a median of -$26.3 million in 2024.
• Annual changes were most pronounced in 2022 — Free Cash Flow slumped 196.56% — and 2023, when it advanced 16.48%.
• Olema Pharmaceuticals' Free Cash Flow stood at -$19.9 million in 2022, then climbed by 7.08% to -$18.5 million in 2023, then tumbled by 42.26% to -$26.3 million in 2024, then slumped by 45.82% to -$38.3 million in 2025, then decreased by 19.99% to -$46.0 million in 2026.
• Business Quant data shows OLMA's Free Cash Flow at -$46.0 million in Q1 2026, -$38.3 million in Q4 2025, and -$34.5 million in Q3 2025.